Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 6/20 | 0.37 |
| ▸ | EDNRA | P25101 | 6/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396298 | 0.78 | S1PR1 (0.35) | ALDH1A1SCN9ANPC1 | |
| SCHEMBL26581277 | 0.77 | BRD4 (0.50) | BRD4KDM4EALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL28132230 | 0.76 | SCN9A (0.38) | SCN9A | |
| SCHEMBL28133018 | 0.72 | KDM4E (0.45) | BRD4KDM4EALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL31400614 | 0.70 | PARP1 (0.43) | BRD4KDM4EALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL11395443 | 0.69 | ALDH1A1 (0.37) | KDM4EALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL26581232 | 0.68 | KDM4E (0.50) | BRD4KDM4EALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL11401697 | 0.68 | MAPT (0.32) | ALDH1A1 | |
| SCHEMBL7317623 | 0.68 | TP53 (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28132234 | 0.68 | KDM4E (0.38) | BRD4KDM4EALDH1A1BRPF1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169680-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| CN-106488916-A | The new 2,5 substituted miazines as PDE inhibitor | 格吕伦塔尔有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016008592-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | PDE4B, PDE4A, PDE12 | BRD4 255/4885KDM4E 1006/4885ALDH1A1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.